[{"indications": "Indications\u00a0\n(From Natalizumab: British National Formulary)\nNatalizumab", "name": "NATALIZUMAB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.2 Drugs affecting the immune response", "8.2.4 Other immunomodulating drugs", "Natalizumab", "NATALIZUMAB"], "cautions": "Cautions\u00a0\n(From Natalizumab: British National Formulary)\nNatalizumab and consult product\r\nliterature; prior treatment with immunosuppressants\r\n(increased risk of progressive multifocal leukoencephalopathy); monitor liver function (see below)Liver toxicity\u00a0Liver dysfunction reported; advise patients to seek immediate medical attention if symptoms such\r\nas jaundice or dark urine develop; discontinue\r\ntreatment if significant liver injury occursProgressive multifocal leucoencephalopathy (PML)\u00a0Patients should be informed about the risks of PML before\r\nstarting treatment with natalizumab and again after 2 years; they\r\nshould be given an alert card which includes information about the\r\nsymptoms of PML (see also %s\n(From Natalizumab: British National Formulary)\nNatalizumab)Hypersensitivity reactions\u00a0Patients\r\nshould be told the importance of uninterrupted dosing, particularly\r\nin the early months of treatment (intermittent therapy may increase\r\nrisk of sensitisation)", "side-effects": "Side-effects\u00a0\n(From Natalizumab: British National Formulary)\nNatalizumab; also urinary-tract infection,\r\nnasopharyngitis, autoantibodies, and arthralgia; less commonly hypersensitivity reactions (see above); liver toxicity also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129975.htm", "doses": ["By intravenous infusion, adult over 18 years, 300\u00a0mg once every 4 weeks; discontinue\r\nif no response after 6 months"], "pregnancy": "Pregnancy\u00a0avoid unless essential\u2014toxicity in animal studies"}]